" /> Vodobatinib - CISMeF





Preferred Label : Vodobatinib;

NCIt synonyms : Bcr-Abl Kinase Inhibitor K0706; 4-Methyl-3-quinolin-3-ylethynylbenzoic Acid N'-(2-chloro-6-methylbenzoyl) Hydrazide;

NCIt definition : An orally bioavailable, Bcr-Abl tyrosine kinase inhibitor (TKI), with potential antineoplastic activity. Upon administration, vodobatinib selectively targets and binds to the Bcr-Abl fusion oncoprotein, including various Bcr-Abl mutant forms, such as those with the 'gatekeeper' resistance mutation T315I. This inhibits proliferation of Bcr-Abl-expressing tumor cells. The Bcr-Abl fusion protein is an aberrantly activated tyrosine kinase produced by certain leukemia cells. T315I, an amino acid substitution where threonine (T) has been mutated to isoleucine (I) at position 315 in the tyrosine-protein kinase ABL1 portion of the Bcr-Abl fusion protein, plays a key role in resistance to certain chemotherapeutic agents and its expression is associated with poor prognosis.;

UNII : N8Q12KU2SW;

InChIKey : ZQOBVMHBVWNVBG-UHFFFAOYSA-N;

CAS number : 1388803-90-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1388803-90-4 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : SUN K706; WHO 11506; SUN-K706; K-0706; SUN-K0706; SCO-088;

NCI Metathesaurus CUI : CL520597;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
12/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.